Compounding Pharmacies and GLP-1 Medications: What You Need to Know in 2025

Disclaimer: Insurance and cost information changes frequently. Always verify current coverage details with your insurer and prescriber.

What Is a Compounding Pharmacy?

Compounding pharmacies are specialized pharmacies that create customized medications for individual patients. Unlike standard pharmacies that dispense commercially manufactured drugs, compounders mix ingredients from scratch to produce a formulation that is not commercially available — for example, a liquid version of a drug that only comes in pill form, or a specific dosage strength that manufacturers do not make.

Compounding has legitimate and longstanding medical uses. A child who cannot swallow pills may need a liquid compounded version of their medication. A patient allergic to a standard excipient (inactive ingredient) may need a custom formulation without it. A hospice patient may need a combination drug not commercially available. These are the cases compounding was designed for.

The FDA distinguishes between two types of compounding facilities. Section 503A pharmacies compound drugs based on individual patient prescriptions at a traditional pharmacy scale. Section 503B outsourcing facilities are larger operations that can compound drugs in bulk without individual prescriptions, subject to stricter FDA oversight including registration, inspection, and Current Good Manufacturing Practice (CGMP) standards. During the GLP-1 shortage, both types were producing compounded semaglutide and tirzepatide.

How the Shortage Created the Compounding Market

The GLP-1 medication shortage began in earnest in 2022 and persisted through 2024. Demand for semaglutide and tirzepatide — driven by viral social media attention and explosive prescribing growth — vastly outpaced manufacturing capacity. Novo Nordisk and Eli Lilly both invested billions in expanding production, but it takes years to build and validate pharmaceutical manufacturing capacity.

The FDA's response to drug shortages includes placing affected drugs on an official shortage list, which creates a legal pathway for compounders. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can prepare copies of a commercially available drug when that drug appears on the FDA shortage list. This allowed hundreds of compounding pharmacies to begin producing semaglutide and tirzepatide solutions — usually in vials for subcutaneous injection — at prices far below the branded products.

For many patients during this period, compounded GLP-1s were the only accessible option. Branded Wegovy and Zepbound were back-ordered for months. Compounders filled a real gap, and for patients who could work with a physician comfortable prescribing compounded medications, costs of $150–$350 per month made treatment possible for people who otherwise could not have afforded it.

The Legal Status After the Shortage Ended

The FDA removed semaglutide from its drug shortage list in early 2025, citing restored supply of all doses and formulations of Ozempic and Wegovy. The FDA subsequently provided a wind-down period — approximately 60 days for 503A pharmacies and 90 days for 503B outsourcing facilities — during which compounders were expected to stop producing compounded semaglutide.

After this wind-down period, compounding semaglutide became legally impermissible for the vast majority of pharmacies. The law is clear: compounders cannot produce copies of commercially available drugs that are not on the shortage list unless they meet the narrow exception for patient-specific clinical needs (such as a documented allergy to a specific excipient in the commercial product). Compounding solely because the commercial drug is more expensive is not a qualifying reason under FDA regulations.

The situation with tirzepatide has been more litigated. Some compounding pharmacy associations challenged the FDA's shortage removal in court, and the legal proceedings created a temporary continuation of compounding activity in early 2025. However, the FDA has been clear that its position is that the tirzepatide shortage has also resolved, and enforcement actions against compounders of both drugs are expected to increase through 2025.

For patients: using compounded semaglutide or tirzepatide obtained after shortage removal carries real risk. If a pharmacy is producing these drugs outside the legal framework, it may also be operating below safety standards. And if enforcement escalates, your supply could be disrupted abruptly with no notice.

Quality, Safety, and Dosing Concerns

Even setting aside the legal issues, compounded GLP-1 medications have raised legitimate patient safety concerns that deserve serious attention.

Dosing accuracy is one of the primary concerns. Commercial semaglutide pens are manufactured to pharmaceutical-grade precision — each dose delivers exactly the labeled amount. Compounded vials require the patient (or a caregiver) to draw up the correct volume using a syringe, which introduces the potential for human error. Dosing errors with GLP-1 medications can cause significant gastrointestinal side effects at too high a dose or inadequate therapeutic effect at too low a dose.

Contamination and sterility are additional risks. The FDA has issued warnings specifically about compounded semaglutide products found to contain microbial contamination, incorrect concentration of the active ingredient, or unapproved additives. Some compounders have used semaglutide sodium or semaglutide acetate — chemical forms of semaglutide that are not the same as the pharmaceutical-grade semaglutide base used in Ozempic and Wegovy and that have not been studied in humans for safety and efficacy.

The FDA has received adverse event reports from patients using compounded GLP-1 products, including reports of hospitalizations. While the absolute numbers are low relative to the scale of use, they reflect real risks from inconsistent product quality that do not exist with the branded pharmaceuticals.

Legitimate Alternatives to Compounding

The good news is that the cost-savings rationale for compounded GLP-1s has weakened considerably as legitimate access programs have expanded. For most patients who were using compounded medications, better options now exist.

Eli Lilly's LillyDirect program offers Zepbound vials at self-pay prices in the $349–$549 per month range depending on dose. These are genuine commercial pharmaceutical products manufactured under FDA oversight, not compounded copies. For patients who were paying $200–$350 per month for compounded tirzepatide, LillyDirect offers comparable or better pricing for the real drug.

Manufacturer savings cards for commercially insured patients can bring Ozempic, Wegovy, Mounjaro, and Zepbound costs to $25 per month. If you were using compounded medication because your insurance denied the branded drug, it is worth re-evaluating whether an insurance appeal, a different plan during open enrollment, or a different diagnosis code could make the branded drug accessible.

Patient Assistance Programs from both Novo Nordisk (NovoCare) and Eli Lilly (Lilly Cares) provide free medication to income-eligible patients who lack coverage. These programs have expanded their capacity as demand has grown, and processing times have improved.

Questions to Ask Before Using a Compounding Pharmacy

If, after reading this guide, you are still considering a compounding pharmacy — perhaps due to a documented clinical need for a customized formulation — there are questions you should ask before proceeding.

Is the pharmacy registered as a 503B outsourcing facility? 503B facilities are subject to FDA inspection and CGMP standards. You can verify registration on the FDA's website at fda.gov. A 503A pharmacy can only legally compound for a specific patient prescription, not in bulk; verify that a prescription from your physician is in place before any medication is dispensed.

What form of semaglutide or tirzepatide are they using? The answer should be the base form of the active pharmaceutical ingredient — not semaglutide sodium, semaglutide acetate, or tirzepatide acetate. These salt forms have not been clinically validated for the same use and may have different bioavailability.

Does the pharmacy conduct potency and sterility testing? Any legitimate compounding pharmacy should be able to show you third-party certificate of analysis (CoA) documentation confirming that each batch has been tested for potency, sterility, and the absence of endotoxins. If they cannot or will not provide this, that is a significant red flag.

What is the legal basis for compounding after the shortage ended? If they are still producing semaglutide after early 2025, ask them to explain specifically under which FDA exception they are operating. If they cannot give you a clear, specific answer, you should be concerned about the legality of what you are purchasing.

Does your physician support this? If your prescribing physician is not comfortable writing a prescription for a compounded GLP-1 after shortage removal, that discomfort is clinically and legally informed. Do not seek out a different prescriber solely to get a compounded prescription — work with your physician to find a solution within the range of FDA-approved options.